Group 1 - Vertical Aerospace Ltd. (EVTL) shares have increased by 64.9% over the past four weeks, closing at $5.69, with a mean price target of $10.30 indicating a potential upside of 81% [1] - The average price targets range from a low of $2 to a high of $15, with a standard deviation of $5.14, suggesting variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 4.9% over the past month, indicating positive sentiment among analysts [12] - EVTL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide guidance on the direction of price movement [13]

Group 1 - Candel Therapeutics, Inc. (CADL) closed at $5.11, with an 11.8% gain over the past four weeks, and a mean price target of $21 suggests a 311% upside potential [1] - The average price targets range from a low of $15 to a high of $25, with a standard deviation of $4.90, indicating a variability in estimates; the lowest estimate suggests a 193.5% increase, while the highest indicates a 389.2% upside [2] - Analysts show strong agreement on CADL's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for CADL's current year earnings has increased by 17.5%, with one estimate moving higher and no negative revisions [12] - CADL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13]

Group 1 - Immunocore Holdings PLC (IMCR) closed at $29.06, with a 2.3% gain over the past four weeks, and has a mean price target of $62.29, indicating an upside potential of 114.4% [1] - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.44, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [13]

Core Viewpoint - Stoke Therapeutics, Inc. (STOK) has shown a significant price increase of 25.2% over the past four weeks, with a mean price target of $22.38 indicating a potential upside of 132.4% from the current price of $9.63 [1] Price Targets and Analyst Consensus - The average price target for STOK ranges from a low of $15 to a high of $35, with a standard deviation of $6.82, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 55.8%, while the most optimistic estimate points to a 263.5% upside [2] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising STOK's earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 59.1% over the past month, with three estimates going higher and no negative revisions [12] - STOK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - MoonLake Immunotherapeutics (MLTX) shows significant upside potential with a mean price target of $76.43, indicating a 106.6% increase from the current price of $36.99 [1] Price Targets and Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $13.12, suggesting variability among analysts [2] - The lowest estimate of $55 indicates a 48.7% increase, while the highest estimate predicts a surge of 181.2% to $104 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 1.7% over the past month, with two estimates going higher and no negative revisions [12] - MLTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - QuinStreet (QNST) closed at $15.88, with a 1.4% gain over the past four weeks, and a mean price target of $28.40 suggests a 78.8% upside potential [1] - The mean estimate includes five short-term price targets with a standard deviation of $5.90, indicating variability; the lowest estimate of $19 represents a 19.7% increase, while the highest target of $35 suggests a 120.4% surge [2] - Analysts show strong agreement on QNST's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 31.4% over the past month, with two estimates rising and one falling [12] - QNST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]

Group 1 - Pagaya Technologies Ltd. (PGY) closed at $14.96, with a 49.8% gain over the past four weeks, and a mean price target of $22.69 suggests a 51.7% upside potential [1] - The average price targets from analysts range from a low of $13.75 to a high of $36, with a standard deviation of $7.04, indicating variability in estimates [2] - Analysts show strong agreement on PGY's ability to report better earnings, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for PGY's current year earnings has increased by 2.8% over the last 30 days, with no negative revisions [12] - PGY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [13]

Group 1 - Xperi (XPER) has shown a significant price increase of 27.7% over the past four weeks, with a mean price target of $18.25 indicating an upside potential of 118.8% [1] - The average price target ranges from a low of $12 to a high of $30, with a standard deviation of $8.02, suggesting variability in analysts' estimates [2] - The consensus price target is not the sole metric for investment decisions, as analysts' ability to set accurate price targets has been questioned [3] Group 2 - Strong agreement among analysts regarding XPER's earnings prospects, indicated by positive earnings estimate revisions, supports the expectation of stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for XPER's current year earnings has increased by 46.2%, with no negative revisions [12] - XPER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Core Viewpoint - Sangoma Technologies Corporation (SANG) has shown a significant price increase of 29.2% over the past four weeks, with a mean price target of $8.36 indicating a potential upside of 40.5% from the current price of $5.95 [1] Price Targets and Analyst Consensus - The average price target consists of four estimates ranging from a low of $7.94 to a high of $9.50, with a standard deviation of $0.76, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a potential increase of 33.5%, while the highest suggests a 59.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding SANG's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 8.3%, with two estimates moving higher and no negative revisions [12] - SANG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Group 1 - Trevi Therapeutics, Inc. (TRVI) shares have increased by 4.1% over the past four weeks, closing at $6.46, with a mean price target of $19.06 indicating a potential upside of 195.1% [1] - The average of eight short-term price targets ranges from a low of $11 to a high of $29, with a standard deviation of $6.01, suggesting a potential increase of 70.3% to 348.9% from the current price level [2] - Analysts show strong agreement regarding TRVI's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TRVI's current year has increased by 21.5% over the past month, with five estimates rising and no negative revisions [12] - TRVI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]